LRMR
NASDAQLarimar Therapeutics Inc.
News · 26 weeks42+33%
2025-12-142026-06-07
Mix1990d
- SEC Filings8(42%)
- Insider6(32%)
- Offering2(11%)
- Other2(11%)
- Analyst1(5%)
Latest news
25 items- ANALYSTAnalyst initiated coverage on Larimar Therapeutics with a new price targetAnalyst initiated coverage of Larimar Therapeutics with a rating of Overweight and set a new price target of $9.00
- INSIDERSEC Form 4 filed by * Director by Deputization Flynn James E4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERSEC Form 4 filed by Director Leff Jonathan S4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERSEC Form 4 filed by Director Sherman Jeffrey W4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERSEC Form 4 filed by Director Truitt Joseph4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERSEC Form 4 filed by Director Thomas Frank E4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERSEC Form 4 filed by Director Hamilton Thomas Edward4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form 10-Q filed by Larimar Therapeutics Inc.10-Q - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics Reports First Quarter 2026 Financial and Business UpdateIntending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-reviewed journalTopline open label study data to support BLA submission expected in Q2 2026$200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, with projected cash runway into the second quarter of 2027 BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Larimar Therapeutics Inc.SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
- PRLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's AtaxiaBALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled "Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling" in the journal Clinical and Translational Science, an official peer-reviewed publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). The article is now available online (link). Nonclinical data across mice, rats, and non-human primates consistently showed that treatm
- SECSEC Form DEF 14A filed by Larimar Therapeutics Inc.DEF 14A - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form PRE 14A filed by Larimar Therapeutics Inc.PRE 14A - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form S-8 filed by Larimar Therapeutics Inc.S-8 - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECSEC Form 10-K filed by Larimar Therapeutics Inc.10-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsBreakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA's review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patient expected mid-2026Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved
- SECLarimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
- PRLarimar Therapeutics to Participate in Upcoming Investor Conferences in MarchBALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the following upcoming investor conferences taking place in Miami Beach, FL. Presentation details can be found below. Leerink Partners Global Healthcare ConferenceDate: Tuesday, March 10, 2026Time: 8:40 AM ETWebcast Link:https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/FAcSQYGbUgaSReiyPwMwXA The Citizens Life Sciences ConferenceDate: Wednesday, March 11, 2026Tim
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Larimar Therapeutics Inc.SCHEDULE 13D/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
- INSIDER* Director by Deputization Flynn James E bought $25,000,000 worth of shares (5,000,000 units at $5.00) (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERDirector Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
- INSIDERDirector Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
LRMR FAQ
7 questionsWhat does Larimar Therapeutics Inc. do?
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.Where does LRMR stock trade?
Larimar Therapeutics Inc. (LRMR) is listed on NASDAQ.What sector and industry is LRMR in?
Larimar Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Larimar Therapeutics Inc. go public?
Larimar Therapeutics Inc. (LRMR) completed its IPO in 2014.What are analysts saying about LRMR?
Larimar Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $900.00 price target on 2026-05-27.What companies are similar to LRMR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LRMR side-by-side with any of them on Quantisnow.How can I track LRMR on Quantisnow?
Quantisnow aggregates Larimar Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LRMR to receive live email and push alerts on every new disclosure.